Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis
May 25 2016 - 1:00AM
Business Wire
– Supported by findings from a large
global survey of RMS patients and care partners, vs.MS provides
information and tools aimed at driving better informed care
–
Sanofi Genzyme, the specialty care global business unit of
Sanofi, announced today the launch of vs.MS, a global initiative
focused on highlighting and addressing the sometimes debilitating
symptoms that accompany MS, as well as their daily impact on people
living with and affected by the disease.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160524006631/en/
vs.MS Survey Results (Graphic: Sanofi
Genzyme)
This World MS Day, Sanofi Genzyme is putting a call out to the
MS community to learn more about the real impact of the disease and
to declare themselves vs.MS on the campaign website, www.vs-MS.com.
For each vs.MS declaration, Sanofi Genzyme will make a donation to
the Multiple Sclerosis International Federation (MSIF).
To inform the vs.MS campaign, a global survey was fielded among
more than 1,500 people living with relapsing MS (RMS) and their
care partners in seven countries: Australia, Canada, France, Italy,
Spain, the United Kingdom and the United States. Results from the
survey reveal the physical and emotional toll that RMS patients
face on a day-to-day basis. Additional survey findings are
available on the vs.MS website. Some findings include:
- More than half of respondents living
with RMS find that issues with memory limit their daily
activities
- More than half of respondents living
with RMS say their ability to process information has slowed
down
- Nearly half of respondents living with
RMS feel limited by depression or anxiety
- More than half of respondents living
with RMS feel lonely or isolated because of their RMS
- Two-thirds of respondents living with
RMS say their disease has affected their ability to keep their
job
- More than one-third of respondents feel
urinary problems associated with their RMS are a factor in the
decisions they make when planning to leave the house
- More than half of care partner
respondents do not discuss their fear of RMS progressing to avoid
upsetting the person they care for
“As part of our ongoing commitment to improving the lives of
people affected by this debilitating disease, we are proud to
launch vs.MS,” said Carole Huntsman, Global Multiple Sclerosis
Lead, Sanofi Genzyme. “The compelling findings from this survey
broaden our understanding of the true cognitive and emotional toll
that MS takes, and will help guide our efforts to better partner
with the community to meet the overall needs of MS patients.”
To arm the MS community with the tools and resources they need
to be vs.MS, the campaign website includes videos, educational
modules and survey results highlighting the real burden of the
disease.
To learn more about vs.MS and view the survey findings, visit
www.vs-MS.com and follow along on social media via the campaign
hashtag, #vsMS.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.
Sanofi is organized into five global business units: Diabetes and
Cardiovascular, General Medicines and Emerging Markets, Sanofi
Genzyme, Sanofi Pasteur and Merial.
Sanofi Genzyme focuses on developing specialty treatments for
debilitating diseases that are often difficult to diagnose and
treat, providing hope to patients and their families. Learn more
at www.sanofigenzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation.
Sanofi® is a registered trademark of Sanofi. All rights
reserved.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group’s ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2015. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160524006631/en/
Sanofi Genzyme Media RelationsErin Walsh, +1
617-768-6881Erin.Walsh@genzyme.com
Banco Santander (NYSE:SAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Banco Santander (NYSE:SAN)
Historical Stock Chart
From Sep 2023 to Sep 2024